Novartis AG Sponsored ADR (NVS)
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite BioAge's clinical setback, its substantial cash position and Novartis deal offer potential for a strategic pivot towards neuroinflammation and age-related conditions. Novartis benefits from BioAge's longevity data, potentially enhancing its neuroscience pipeline and mitigating revenue risks from upcoming loss of exclusivity on key drugs.
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 patent expirations for key drugs like Entresto, Promacta, and Tasigna triggered a sell-off. Novartis' robust pipeline and new product launches are expected to offset losses from patent expirations, supporting long-term growth and a "Buy" rating.
AI, vaccine distrust, & the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
Here's Why Novartis (NVS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya.
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected.
NVS vs. LLY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Novartis (NVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novartis: Time To Increase
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
